Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Alabama: - University of Alabama — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Alabama: - University of Alabama at Birmingham Children's of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: David Reardon, MD
NCT ID: NCT02977780
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Academic/Other
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05084430
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Sponsor: Boston Scientific Corporation
NCT ID: NCT05303467
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combi…
Sponsor: Orbus Therapeutics, Inc.
NCT ID: NCT05879367
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Academic/Other
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03911388
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama: - Massive Bio SYNERGY-AI site — Birmingham, Alabama
- Massive Bio SYNERGY-AI site — Mobile, Alabama
NA Recruiting Academic/Other
Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
Sponsor: University of Alabama at Birmingham
NCT ID: NCT06857006
Sites in Alabama: - University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center — Birmingham, Alabama